EUVIMEDEUVIMED entdecken
Crossref

Clinical research analysis of [225Ac]Ac-PSMA-617 therapy for [177Lu]Lu-PSMA-refractory metastatic castration-resistant prostate cancer

Zijuan Rao, Jiao Ma, Yangqing Jiangchu, Weiyu Yang, Fengyu Zhang, Meiling Hu, Chunyin Zhang, Yue Chen

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-07778-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Zijuan Rao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Heterocyclic Compounds, 1-Ring, Dipeptides, Lutetium. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Southwest Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The aim of this evaluation was to identify the safety and efficacy for [225Ac]Ac-labeled prostate-specific membrane antigen-617 therapy in a retrospectively analyzed group of patients after [177Lu]Lu-PSMA therapy. METHODS: Metastatic castration-resistant prostate cancer patients after [177Lu]Lu-PSMA were selected for treatment with 1 ~ 5 cycles of [225Ac]Ac-PSMA-617. Prostate-specific antigen and blood cell count were measured at the 2nd, 4th, and 8th week after treatment. [68Ga]Ga-PSMA-11 PET/CT was used for baseline staging and imaging follow-up at the 2nd month. Safety was assessed according to the Common Terminology Criteria for Adverse Events version 5.0. RESULTS: Eighteen patients were treated per protocol with a mean activity of 6.1 MBq in each cycle. 72.22% had a PSA decline at any degree, 55.56% had a PSA decline at more than 50%, and 38.89% had a PSA decline at more than 80%. According to PSMA PET progression criteria, disease control was achieved in 38.89% of the patients. The median progression-free survival under [225Ac]Ac-PSMA-617 after [177Lu]Lu-PSMA therapy was 4 mo; the median overall survival was 17 mo. Any decline in PSA, a decline in PSA of ≥ 50%, prior treatment with at least 2 cycles and at least 3 cycles of [177Lu]Lu-PSMA were all significantly associated with PFS. The median PFS was significantly longer for patients receiving ≥ 2 cycles of [177Lu]Lu-PSMA therapy (4.8 mo, 95% CI: 3.7-5.9) compared to those receiving only 1 cycle (2.4 mo, 95% CI: 1.6-3.2). Median PFS was 5.3 mo (95% CI: 4.0-6.5) with ≥ 3 cycles of [177Lu]Lu-PSMA therapy, compared to 3 mo (95% CI: 2.0-4.0) in those receiving < 3 cycles.Toxic reactions and adverse effects were mostly grade I ~ III and anemia is the most common hematological toxic reaction. The change in hemoglobin levels before and after [225Ac]Ac-PSMA treatment was statistically significant (p = 0.006). All patients experienced xerostomia to varying degrees. CONCLUSION: For metastatic castration-resistant prostate cancer patients intolerant or unresponsive to [177Lu]Lu-PSMA treatment, [225Ac]Ac-PSMA-617 demonstrated significant and safe antitumor effects with relatively low treatment-related toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantHeterocyclic Compounds, 1-RingDipeptidesLutetiumActiniumHumansMaleAgedNeoplasm MetastasisMiddle AgedPositron Emission Tomography Computed TomographyRetrospective StudiesProstate-Specific AntigenRadioisotopesTreatment OutcomeRadiopharmaceuticalsAged, 80 and over

Stichwörter der Autor:innen

PSA responsePSMA[177Lu]Lu[225Ac]AcmCRPC

Substanzen

Heterocyclic Compounds, 1-RingDipeptidesLutetium(225)Ac-PSMA-617Lutetium-177Prostate-Specific AntigenActiniumRadioisotopesRadiopharmaceuticalslutetium (177Lu) vipivotide tetraxetan

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China.
  • Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province, Luzhou, Sichuan, PR China.
  • Laboratory for Targeted Radiopharmaceuticals Creation, Luzhou, Sichuan, PR China.
  • Institute of Nuclear Medicine, Southwest Medical University, No. 25, Taiping St, Sichuan, 646000, Luzhou, PR China.
  • Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China. chenyue5523@126.com.
  • Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province, Luzhou, Sichuan, PR China. chenyue5523@126.com.

Förderung

  • Southwest Medical University

Zitieren

APA

Rao, Z., Ma, J., Jiangchu, Y., Yang, W., Zhang, F., Hu, M., Zhang, C., & Chen, Y. (2026). Clinical research analysis of [225Ac]Ac-PSMA-617 therapy for [177Lu]Lu-PSMA-refractory metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07778-6

Vancouver

Rao Z, Ma J, Jiangchu Y, Yang W, Zhang F, Hu M, et al. Clinical research analysis of [225Ac]Ac-PSMA-617 therapy for [177Lu]Lu-PSMA-refractory metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-07778-6

BibTeX
@article{Rao2026,
  author = {Rao, Zijuan and Ma, Jiao and Jiangchu, Yangqing and Yang, Weiyu and Zhang, Fengyu and Hu, Meiling and Zhang, Chunyin and Chen, Yue},
  title = {Clinical research analysis of [225Ac]Ac-PSMA-617 therapy for [177Lu]Lu-PSMA-refractory metastatic castration-resistant prostate cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-07778-6}
}
Kostenlos starten →